secukinumab — drug repurposing hypotheses

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

secukinumab appears in hypotheses across 7 disease domains: ALS, Depression, Epilepsy, Inflammatory bowel disease, Multiple sclerosis, Pancreatic cancer, Rheumatoid arthritis. Shared mediators that recur across at least two of those domains: IL-17A.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for secukinumab

ALS 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
IL-17A	motor neuron viability	0.230	Mid	novel signal	none
IL-17A	neurite length	0.230	Mid	novel signal	none

Depression 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
IL-17A	antidepressant treatment resistance	0.230	Mid	novel signal	none

Epilepsy 4

Mediator	Outcome	Score	Tier	Lit. status	Trial
IL-17A	anxiety	0.230	Mid	reproduces known	none
IL-17A	LTP dysfunction	0.230	Mid	novel signal	none
IL-17A	neural progenitor proliferation	0.230	Mid	novel signal	none
IL-17A	hippocampal neuronal death	0.230	Mid	novel signal	none

Inflammatory bowel disease 4

Mediator	Outcome	Score	Tier	Lit. status	Trial
IL-17A	IBD	0.271	High	reproduces known	completed
IL-17A	fibrosis	0.230	Mid	reproduces known	none
IL-17A	endoscopic severity	0.230	Mid	novel signal	none
IL-17A	Behcet's uveitis	0.230	Mid	reproduces known	completed

Multiple sclerosis 8

Mediator	Outcome	Score	Tier	Lit. status	Trial
IL-17A	cognitive impairment	0.271	High	partial evidence	none
IL-17A	CNS autoimmunity	0.230	Mid	novel signal	completed
IL-17A	response to interferon-beta therapy	0.230	Mid	novel signal	none
IL-17A	EAE susceptibility	0.230	Mid	novel signal	none
IL-17A	EAE	0.230	Mid	novel signal	none
IL-17A	intestinal homeostasis	0.230	Mid	partial evidence	none
IL-17A	EAE severity	0.230	Mid	novel signal	none
IL-17A	BBB dysfunction	0.230	Mid	novel signal	none

Pancreatic cancer 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
IL-17A	acinar-ductal metaplasia	0.230	Mid	novel signal	none
IL-17A	islet β-cell apoptosis	0.230	Mid	novel signal	none

Rheumatoid arthritis 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
IL-17A	DAS28	0.220	Mid	reproduces known	none
IL-17A	early rheumatoid arthritis	0.220	Mid	novel signal	none

← All drugs